Enzymatica, which specialises in enzyme-based medical devices for respiratory health, has so far had a strong 2025. Sales for the first half of the year amounted to SEK 20,6 million, an increase of around 30 percent compared with the same period in 2024. Growth is primarily driven by strong performance in Sweden, where ColdZyme sales rose by 23,8 percent during the half-year, reaching a 5 percent market share – three times faster than the market overall.
Despite the positive development in Sweden, international expansion is expected to drive Enzymatica’s long-term growth. The company is working actively to secure new partnerships, with discussions intensifying during the year. The initial focus is on EU markets where ColdZyme is CE marked under MDR.
Additional opportunities are being evaluated case by case, but the company sees a potential paradigm shift following the FDA’s XNUMX decision on the inefficacy phenylephrine – expected to fuel the search for effective alternatives.
New flavour strengthens the portfolio
At the same time, the company continues to build an attractive product portfolio and recently announced the addition of Eucalyptus as a new flavour. The new variant is based on the same barrier technology, which forms a protective layer in the throat and reduces viral load by up to XNUMX percent, according to independent studies [1]
Clinical data from University of Kent and University of Vienna[1]support that the product shortens the duration of a cold by an average of XNUMX percent and alleviates symptoms. The Eucalyptus flavour is designed to appeal to consumers who associate the herb with freshness and easy breathing, complementing the existing Menthol and Strawberry flavours.
– With ColdZyme Eucalyptus, we want to give consumers another choice without compromising on quality or performance. Many associate eucalyptus with fresh air and easy breathing – making it a natural complement to our existing product portfolio, says Claus EgstrandCEO of Enzymatica, in a press release.
The launch will initially take place in Sweden through pharmacies and online, just in time for the upcoming cold season.
References
[1] Davison G et al 2025 ColdZyme® reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses. The Journal of Physiology. 2025;603(6):1483–1501. doi:10.1113/JP288136. PubMed: 40019230. https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136